A Phase-I/II Trial of Oral Hydroxyurea in Chronic Hepatitis C Patients
Phase 1
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000003131
- Lead Sponsor
- Yokohama City University Medical Center Gastroenterological Center
- Brief Summary
Recommended dose (RD) was decided as 1500mg/day.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnant Women Patients with Severe heart disease Patients with Severe DM, HT Patients without selectable factors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PhaseI:The safety PhseII:Antiviral effect
- Secondary Outcome Measures
Name Time Method PhaseI:Antiviral effect PhaseII: The safety, ALT change